Mortality Lower With GLP-1 Receptor Agonist Use in T2D, Especially in Those With OSA
GLP-1 RAs for type 2 diabetes significantly lower one-year mortality, especially in those also diagnosed with obstructive sleep apnea.
According to a study presented at CHEST 2025, patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality.
Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving GLP-1RAs.
- A total of 1,799,261 patients with T2DM who were prescribed metformin were identified and stratified into:
- T2DM without OSA prescribed metformin without GLP-1 RAs (60.2 percent)
- T2DM without OSA prescribed metformin and GLP-1 RAs (20 percent)
No direct quote available in the text.
Author's summary: GLP-1 RAs reduce mortality in T2D patients, especially those with OSA.